Literature DB >> 10468339

Prognostic factors relating to survival in uterine endometrioid carcinoma.

M Hirai1, M Hirono, T Oosaki, Y Hayashi, T Yoshihara, O Matsuzaki.   

Abstract

OBJECTIVE: Epidemiologic and clinicohistopathologic prognostic factors of uterine endometrioid carcinomas were analyzed. The association of estrogen related factors, focused on adenomyosis in the prognosis of endometrioid carcinomas was also examined.
METHODS: Risk factors of surgically treated 286 patients with endometrioid carcinoma (Stage I-III) were statistically analyzed.
RESULTS: Overall a recurrence-free 5-year survival rate was 81% (Stage I, 94%, Stage II, 71% and Stage III, 40%). Significant prognostic factors were lymph node metastases (P = 0.0035) and serosal/parametrial invasion (P = 0.014) by multivariate analysis. Endometrioid carcinomas with co-existing adenomyosis tend to be associated with endometrial hyperplasia (P = 0.04, Fisher's exact test), diagnosed in less invasive status (myometrial invasion, P = 0.004 and serosal/parametrial invasion, P = 0.006) and therefore have a favorable prognosis (P = 0.01, log rank test).
CONCLUSIONS: A favorable prognosis of endometrioid carcinomas with co-existing estrogen related factors (adenomyosis and endometrial hyperplasia) was suggested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468339     DOI: 10.1016/s0020-7292(99)00067-3

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  4 in total

1.  Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.

Authors:  Marina Stasenko; Noah Feit; Simon S K Lee; Cassandra Shepherd; Robert A Soslow; Karen A Cadoo; Kaled Alektiar; Edaise M Da Silva; Ana Paula Martins Sebastião; Mario M Leitao; Ginger Gardner; Pier Selenica; Nadeem R Abu-Rustum; Britta Weigelt; Jennifer J Mueller
Journal:  Int J Gynecol Cancer       Date:  2020-05-05       Impact factor: 3.437

2.  Long-term survival of endometrioid endometrial cancer patients.

Authors:  Leszek Gottwald; Piotr Pluta; Janusz Piekarski; Michał Spych; Katarzyna Hendzel; Katarzyna Topczewska-Tylinska; Dariusz Nejc; Robert Bibik; Jerzy Korczyński; Aleksandra Ciałkowska-Rysz
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

3.  Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients.

Authors:  Alvaro Tejerizo-García; Jesús S Jiménez-López; José L Muñoz-González; Sara Bartolomé-Sotillos; Laura Marqueta-Marqués; Gregorio López-González; José F Pérez-Regadera Gómez
Journal:  Onco Targets Ther       Date:  2013-09-16       Impact factor: 4.147

4.  Adjuvant therapy of endometrial cancer: "taxane or not taxane, this is the question".

Authors:  Vito Lorusso; Simona Vallarelli; Francesco Giotta
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.